Twenty-five patients with acute non-lymphoblastic leukemia (ANLL) in first complete remission underwent autologous bone marrow transplantation (ABMT) between March 1984 and March 1988. The high-dose therapy employed included cyclophosphamide followed by total body irradiation (10 Gy), administered as a single dose. The median time from complete remission to ABMT was 5 months (range 2-9 months). Thirteen (52%) patients remain in complete remission 10-51 months (median 25 months) after ABMT and 14-60 months (median 32 months) after achieving complete remission. Causes of death were recurrent leukemia (five patients), parenchymal toxicities (acute respiratory distress syndrome, veno-occlusive disease) (three patients), cerebral haemorrhage (on...
Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) may provide an alte...
Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (II CR) to B...
One hundred patients with B-cell non-Hodgkin's lym-phoma (NHL) in sensitive relapse or incomple...
Between 1980 and 1985, 175 patients with acute leukaemia in first or subsequent complete remission (...
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than ...
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than ...
Of 455 acute nonlymphocytic leukemia (ANL) patients who underwent marrow transplantation, 95 (21%) r...
Thirty-nine patients with acute myeloblastic leukemia (AML) in first complete remission (CR) were tr...
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than ...
Intensive chemoradiotherapy with autologous bone marrow transplantation (ABMT) has been explored as ...
Thirteen patients with AML in first relapse were treated with high dose combination chemotherapy fol...
We analyzed data from 263 patients with acute myelocytic leukemia (AML) autografted in first remissi...
High dose therapy followed by infusion of autologous bone narrow has become a major treatment option...
High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option fo...
High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option fo...
Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) may provide an alte...
Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (II CR) to B...
One hundred patients with B-cell non-Hodgkin's lym-phoma (NHL) in sensitive relapse or incomple...
Between 1980 and 1985, 175 patients with acute leukaemia in first or subsequent complete remission (...
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than ...
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than ...
Of 455 acute nonlymphocytic leukemia (ANL) patients who underwent marrow transplantation, 95 (21%) r...
Thirty-nine patients with acute myeloblastic leukemia (AML) in first complete remission (CR) were tr...
One hundred and seven consecutive patients with acute non-lymphocytic leukemia (ANL) aged less than ...
Intensive chemoradiotherapy with autologous bone marrow transplantation (ABMT) has been explored as ...
Thirteen patients with AML in first relapse were treated with high dose combination chemotherapy fol...
We analyzed data from 263 patients with acute myelocytic leukemia (AML) autografted in first remissi...
High dose therapy followed by infusion of autologous bone narrow has become a major treatment option...
High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option fo...
High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option fo...
Intensive chemotherapy followed by autologous bone marrow transplantation (ABMT) may provide an alte...
Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (II CR) to B...
One hundred patients with B-cell non-Hodgkin's lym-phoma (NHL) in sensitive relapse or incomple...